PPARs and Angiogenesis—Implications in Pathology
Open Access
- 9 August 2020
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16), 5723
- https://doi.org/10.3390/ijms21165723
Abstract
Peroxisome proliferator-activated receptors (PPARs) belong to the family of ligand-activated nuclear receptors. The PPAR family consists of three subtypes encoded by three separate genes: PPARα (NR1C1), PPARβ/δ (NR1C2), and PPARγ (NR1C3). PPARs are critical regulators of metabolism and exhibit tissue and cell type-specific expression patterns and functions. Specific PPAR ligands have been proposed as potential therapies for a variety of diseases such as metabolic syndrome, cancer, neurogenerative disorders, diabetes, cardiovascular diseases, endometriosis, and retinopathies. In this review, we focus on the knowledge of PPAR function in angiogenesis, a complex process that plays important roles in numerous pathological conditions for which therapeutic use of PPAR modulation has been suggested.Funding Information
- Fondation ARC pour la Recherche sur le Cancer (PJA 20161204650)
This publication has 164 references indexed in Scilit:
- Angiogenesis and EndometriosisObstetrics and Gynecology International, 2013
- The Anti-tumorigenic Properties of Peroxisomal Proliferator-activated Receptor α Are Arachidonic Acid Epoxygenase-mediatedOnline Journal of Public Health Informatics, 2010
- The transcriptional coactivator PGC-1α mediates exercise-induced angiogenesis in skeletal muscleProceedings of the National Academy of Sciences of the United States of America, 2009
- Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trialThe Lancet, 2009
- Peroxisome proliferator-activated receptor β activation promotes myonuclear accretion in skeletal muscle of adult and aged micePflügers Archiv - European Journal of Physiology, 2009
- PPARs Mediate Lipid Signaling in Inflammation and CancerPPAR Research, 2008
- Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical StudiesPPAR Research, 2008
- PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibitionProceedings of the National Academy of Sciences of the United States of America, 2008
- Transcriptional network governing the angiogenic switch in human pancreatic cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient miceThe EMBO Journal, 2007